The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update

Alzheimer's and Dementia

Volumn 11, Issue 7, 2015, Pages 850-859

  Hendrix, James A ^a   Finger, Brad ^b   Weiner, Michael W ^c,d   Frisoni, Giovanni B ^e   Iwatsubo, Takeshi ^f   Rowe, Christopher C ^g   Kim, Seong Yoon ^h   Guinjoan, Salvador M ⁱ   Sevlever, Gustavo ⁱ   Carrillo, Maria C ^a  

^a ALZHEIMER'S ASSOCIATION   (United States)

^b Independent Science Writer   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^g AUSTIN HEALTH   (Australia)

^h Asian Medical Center   (South Korea)

ⁱ Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Neuroimaging

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARGENTINA; ARTICLE; AUSTRALIA; CEREBROSPINAL FLUID; CLINICAL RESEARCH; EUROPE; HUMAN; INFORMATION PROCESSING; JAPAN; KOREA; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; HEALTH;

ALZHEIMER DISEASE; BIOMARKERS; GLOBAL HEALTH; HUMANS; NEUROIMAGING;

EID: 84937558926     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.05.008     Document Type: Review

References (87)

1. S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C. Jack, W. Jagust, and et al. The Alzheimer's Disease Neuroimaging Initiative Neuroimaging Clin N Am 15 2005 869 877
2. S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C. Jack, W. Jagust, and et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative Cognition Dement 5 2006 56 62
3. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, J. Cedarbaum, and et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Alzheimers Dement 11 2015 865 884
4. P.S. Aisen, R.C. Petersen, M.C. Donohue, A. Gamst, R. Raman, R.G. Thomas, and et al. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans Alzheimers Dement 6 2010 239 246
5. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, and et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
6. P. Scheltens, F. Barkhof, J. Valk, P.R. Algra, R.G. van der Hoop, J. Nauta, and et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity Brain 115 Pt 3 1992 735 748
7. O. Kosunen, H. Soininen, L. Paljärvi, O. Heinonen, S. Talasniemi, and P.J. Riekkinen Sr. Diagnostic accuracy of Alzheimer's disease: a neuropathological study Acta Neuropathol 91 1996 185 193
8. W.A. van Gool, and P. Eikelenboom The two faces of Alzheimer's disease J Neurol 247 2000 500 505
9. J.B. Toledo, S.E. Arnold, K. Raible, J. Brettschneider, S.X. Xie, M. Grossman, and et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre Brain 136 Pt 9 2013 2697 2706
10. J.B. Toledo, N.J. Cairns, X. Da, K. Chen, D. Carter, A. Fleisher, and et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings Acta Neuropathol Commun 1 2013 65
11. A. Korff, C. Liu, C. Ginghina, M. Shi, J. Zhang Alzheimer's Disease Neuroimaging Initiative alpha-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment J Alzheimers Dis 36 2013 679 688
12. J.B. Toledo, A. Korff, L.M. Shaw, J.Q. Trojanowski, and J. Zhang CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease Acta Neuropathol 126 2013 683 697
13. C.R. Jack Jr., M.A. Bernstein, B.J. Borowski, J.L. Gunter, N.C. Fox, P.M. Thompson, and et al. Update on the magnetic resonance imaging core of the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement 6 2010 212 220
14. T.M. Nir, N. Jahanshad, J.E. Villalon-Reina, A.W. Toga, C.R. Jack, M.W. Weiner, and et al. Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging Neuroimage Clin 3 2013 180 195
15. S.M. Landau, C. Breault, A.D. Joshi, M. Pontecorvo, C.A. Mathis, W.J. Jagust, and et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods J Nucl Med 54 2013 70 77
16. S.M. Landau, D. Harvey, C.M. Madison, R.A. Koeppe, E.M. Reiman, N.L. Foster, and et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI Neurobiol Aging 32 2011 1207 1218
17. J.H. Kang, M. Korecka, J.B. Toledo, J.Q. Trojanowski, and L.M. Shaw Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers Clin Chem 59 2013 903 916
18. S.E. O'Bryant Using blood markers for Alzheimer disease in clinical practice? Neurology 79 2012 846 847
19. P.J. Visser, F.R. Verhey, M. Boada, R. Bullock, P.P. De Deyn, G.B. Frisoni, and et al. Development of screening guidelines and clinical criteria for predementia Alzheimer's disease: The DESCRIPA Study Neuroepidemiology 30 2008 254 265
20. M. Korecka, T. Waligorska, M. Figurski, J.B. Toledo, S.E. Arnold, M. Grossman, and et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry J Alzheimers Dis 41 2014 441 451
21. L.A. Beckett, D.J. Harvey, A. Gamst, M. Donohue, J. Kornak, H. Zhang, and et al. The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes Alzheimers Dement 6 2010 257 264
22. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, and et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
23. N.H. Stricker, H.H. Dodge, N.M. Dowling, S.D. Han, E.A. Erosheva, W.J. Jagust, and et al. CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade Brain Imaging Behav 6 2012 599 609
24. S.D. Han, J. Gruhl, L. Beckett, H.H. Dodge, N.H. Stricker, S. Farias, and et al. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's disease Brain Imaging Behav 6 2012 610 620
25. R.Y. Lo, A.E. Hubbard, L.M. Shaw, J.Q. Trojanowski, R.C. Petersen, P.S. Aisen, and et al. Longitudinal change of biomarkers in cognitive decline Arch Neurol 68 2011 1257 1266
26. B.M. Jedynak, A. Lang, B. Liu, E. Katz, Y. Zhang, B.T. Wyman, and et al. A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort Neuroimage 63 2012 1478 1486
27. A. Mouiha, S. Duchesne Alzheimer's Disease Neuroimaging, Initiative Toward a dynamic biomarker model in Alzheimer's disease J Alzheimers Dis 30 2012 91 100
28. X. Yang, M.Z. Tan, and A. Qiu CSF and brain structural imaging markers of the Alzheimer's pathological cascade PLoS One 7 2012 e47406
29. L. Shen, P.M. Thompson, S.G. Potkin, L. Bertram, L.A. Farrer, T.M. Foroud, and et al. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers Brain Imaging Behav 8 2014 183 207
30. J.C. Bis, C. DeCarli, A.V. Smith, F. van der Lijn, F. Crivello, M. Fornage, and et al. Common variants at 12q14 and 12q24 are associated with hippocampal volume Nat Genet 44 2012 545 551
31. J.L. Stein, S.E. Medland, A.A. Vasquez, D.P. Hibar, R.E. Senstad, A.M. Winkler, and et al. Identification of common variants associated with human hippocampal and intracranial volumes Nat Genet 44 2012 552 561
32. S.A. Meda, M.E. Koran, J.R. Pryweller, J.N. Vega, T.A. Thornton-Wells Alzheimer's Disease Neuroimaging Initiative Genetic interactions associated with 12-month atrophy in hippocampus and entorhinal cortex in Alzheimer's Disease Neuroimaging Initiative Neurobiol Aging 34 2013 1518 e9-e18
33. V.K. Ramanan, S. Kim, K. Holohan, L. Shen, K. Nho, S.L. Risacher, and et al. Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks Brain Imaging Behav 6 2012 634 648
34. M.E. Koran, T.J. Hohman, and T.A. Thornton-Wells Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography Hum Genet 133 2014 85 93
35. S. Kim, S. Swaminathan, M. Inlow, S.L. Risacher, K. Nho, L. Shen, and et al. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel PLoS One 8 2013 e70269
36. K. Nho, J.J. Corneveaux, S. Kim, H. Lin, S.L. Risacher, L. Shen, and et al. Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment Mol Psychiatry 18 2013 781 787
37. S. Swaminathan, S. Kim, L. Shen, S.L. Risacher, T. Foroud, N. Pankratz, and et al. Genomic copy number analysis in Alzheimer's disease and mild cognitive impairment: an ADNI Study Int J Alzheimers Dis 2011 2011 729478
38. S. Swaminathan, M.J. Huentelman, J.J. Corneveaux, A.J. Myers, K.M. Faber, T. Foroud, and et al. Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 7 2012 e50640
39. G. Guffanti, F. Torri, J. Rasmussen, A.P. Clark, A. Lakatos, J.A. Turner, and et al. Increased CNV-Region deletions in mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects in the ADNI sample Genomics 102 2013 112 122
40. A.W. Toga, and K. Crawford The informatics core of the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement 6 2010 247 256
41. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, J. Cedarbaum Alzheimer's Disease Neuroimaging Initiative 2014 update of The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 11 2015 6 e1-e120
42. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, R.C. Green, and et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 8 1 Suppl 2012 S1 S68
43. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, R.C. Green, and et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 9 2013 e111 e194
44. D.L. Hill, A.J. Schwarz, M. Isaac, L. Pani, S. Vamvakas, R. Hemmings, and et al. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease Alzheimers Dement 10 2014 421 429.e3
45. D.P. Veitch, K.E. Friedl, and M.W. Weiner Military risk factors for cognitive decline, dementia and Alzheimer's disease Curr Alzheimer Res 10 2013 907 930
46. M.W. Weiner, D.P. Veitch, J. Hayes, T. Neylan, J. Grafman, P.S. Aisen, and et al. Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement 10 3 Suppl 2014 S226 S235
47. Parkinson Progression Marker Initiative The Parkinson Progression Marker Initiative (PPMI) Prog Neurobiol 95 2011 629 635
48. Rammohan K.W. Transformation of MS care in the 21st Century. How NARCRMS will change the way we practice. 6th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Americas Committee for Treatment and Research In Multiple Sclerosis (ACTRIMS). 2014.
49. J. Jovicich, M. Marizzoni, R. Sala-Llonch, B. Bosch, D. Bartrés-Faz, J. Arnold, and et al. Brain morphometry reproducibility in multi-center 3T MRI studies: a comparison of cross-sectional and longitudinal segmentations Neuroimage 83 2013 472 484
50. J. Jovicich, M. Marizzoni, B. Bosch, D. Bartrés-Faz, J. Arnold, J. Benninghoff, and et al. Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects Neuroimage 101C 2014 390 403
51. Jovicich J, Minati L, Marizzoni M, Marchitelli R, Sala-Llonch R, Bartrés-Faz D, et al. Multisite longitudinal reliability of intrinsic fMRI Default Mode Network in healthy elderly subjects: an evaluation of back-projection ICA and seed-based analyses. Neuroimage. In-press.
52. Marchitelli R, Minati L, Marizzoni M, Bosch B, Bartrés-Faz D, W Müller B, et al. Multisite longitudinal reliability of intrinsic fMRI Default Mode Network in healthy elderly subjects: an evaluation of fMRI-based physiological noise correction strategies. Brain Connectivity. In-press.
53. Galluzzi S, et al. Cross-sectional clinical and biomarker features of prodromal Alzheimer's disease in mild cognitive impairment patients of WP5 PharmaCog/E-ADNI study. Alzheimers Dement. In-press.
54. E. Westman, C. Aguilar, J.S. Muehlboeck, and A. Simmons Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment Brain Topogr 26 2013 9 23
55. E. Westman, J.S. Muehlboeck, and A. Simmons Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion Neuroimage 62 2012 229 238
56. F. Mangialasche, E. Westman, M. Kivipelto, J.S. Muehlboeck, R. Cecchetti, M. Baglioni, and et al. Classification and prediction of clinical diagnosis of Alzheimer's disease based on MRI and plasma measures of α-/γ-tocotrienols and γ-tocopherol J Intern Med 273 2013 602 621
57. S.J. Furney, D. Kronenberg, A. Simmons, A. Güntert, R.J. Dobson, P. Proitsi, and et al. Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease - cytokines and MRI measures together predict disease progression J Alzheimers Dis 26 Suppl 3 2011 395 405
58. A.V. Lebedev, E. Westman, G.J. Van Westen, M.G. Kramberger, A. Lundervold, D. Aarsland, and et al. Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness Neuroimage Clin 6 2014 115 125
59. O.M. Doyle, E. Westman, A.F. Marquand, P. Mecocci, B. Vellas, M. Tsolaki, and et al. Predicting progression of Alzheimer's disease using ordinal regression PLoS One 9 2014 e105542
60. C. Aguilar, J.S. Muehlboeck, P. Mecocci, B. Vellas, M. Tsolaki, I. Kloszewska, and et al. Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort Front Aging Neurosci 6 2014 145
61. O.M. Doyle, E. Westman, A.F. Marquand, P. Mecocci, B. Vellas, M. Tsolaki, and et al. Predicting progression of Alzheimer's disease using ordinal regression PLoS One 9 2014 e105542
62. W. Khan, E. Westman, N. Jones, L.O. Wahlund, P. Mecocci, B. Vellas, and et al. Automated hippocampal subfield measures as predictors of conversion from mild cognitive impairment to Alzheimer's disease in two independent cohorts Brain Topogr 2014 Nov 5
63. L. Velayudhan, P. Proitsi, E. Westman, J.S. Muehlboeck, P. Mecocci, B. Vellas, and et al. Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease J Alzheimers Dis 33 2013 755 766
64. M. Thambisetty, A. Simmons, A. Hye, J. Campbell, E. Westman, Y. Zhang, and et al. Plasma biomarkers of brain atrophy in Alzheimer's disease PLoS One 6 2011 e28527
65. L. Velayudhan, R. Killick, A. Hye, A. Kinsey, A. Güntert, S. Lynham, and et al. Plasma transthyretin as a candidate marker for Alzheimer's disease J Alzheimers Dis 28 2012 369 375
66. A. Hye, J. Riddoch-Contreras, A.L. Baird, N.J. Ashton, C. Bazenet, R. Leung, and et al. Plasma proteins predict conversion to dementia from prodromal disease Alzheimers Dement 10 2014 799 807
67. M. Sattlecker, S.J. Kiddle, S. Newhouse, P. Proitsi, S. Nelson, S. Williams, and et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology Alzheimers Dement 10 2014 724 734
68. N. Maikusa, F. Yamashita, K. Tanaka, O. Abe, A. Kawaguchi, H. Kabasawa, and et al. Improved volumetric measurement of brain structure with a distortion correction procedure using an ADNI phantom Med Phys 40 2013 062303
69. T. Yamane, Y. Ikari, T. Nishio, K. Ishii, T. Kato, K. Ito, and et al. Visual-statistical interpretation of 18F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation AJNR Am J Neuroradiol 35 2014 244 249
70. R. Takahashi, K. Ishii, M. Senda, K. Ito, T. Kato, Y. Makishi, and et al. Equal sensitivity of early and late scans after injection of FDG for the detection of Alzheimer pattern: an analysis of 3D PET data from J-ADNI, a multi-center study Ann Nucl Med 27 2013 452 459
71. Y. Ikari, T. Nishio, Y. Makishi, Y. Miya, K. Ito, R.A. Koeppe, and et al. Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multi-center study Ann Nucl Med 26 2012 535 544
72. K.A. Ellis, A.I. Bush, D. Darby, D. De Fazio, J. Foster, P. Hudson the AIBL Research Group The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease Int Psychogeriatr 21 2009 672 687
73. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, G. Jones, and et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283
74. Y.Y. Lim, K.A. Ellis, D. Ames, D. Darby, K. Harrington, R.N. Martins for the AIBL research group Aβ amyloid, cognition and APO E genotype in healthy older adults Alzheimers Dement 9 2013 538 545
75. Y.Y. Lim, V.L. Villemagne, S.M. Laws, R.H. Pietrzak, P.J. Snyder, D. Ames for the AIBL research group APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease Mol Psychiatry 2014 10.1038/mp.2014.123 [Epub ahead of print]
76. C.C. Rowe, P. Bourgeat, K.A. Ellis, B. Brown, Y.Y. Lim, R. Mulligan, and et al. Predicting Alzheimer's disease with beta-amyloid imaging: results from AIBL Ann Neurol 74 2013 905 913
77. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, and et al. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367
78. A. Rembach, N.G. Faux, A.D. Watt, K.K. Pertile, R.L. Rumble, B.O. Trounson the AIBL research group Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease Alzheimers Dement 10 2014 53 61
79. V.B. Gupta, S.M. Laws, V.L. Villemagne, D. Ames, A.I. Bush, K.A. Ellis for the AIBL Research Group Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging Neurology 76 2011 1091 1098
80. S.C. Burnham, N.G. Faux, W. Wilson, S.M. Laws, D. Ames, A.I. Bush the AIBL Research Group A blood based predictor for neocortical amyloid burden in Alzheimer's disease: results from the AIBL study Mol Psychiatry 19 2014 519 526
81. L. Cheng, J.D. Doecke, R.A. Sharples, V.L. Villemagne, C.J. Fowler, A. Rembach for the Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment Mol Psychiatry 2014 10.1038/mp.2014.127 [Epub ahead of print]
82. N.G. Faux, A. Rembach, J. Wiley, K.A. Ellis, D. Ames, C.J. Fowler The AIBL Research Group An anemia of Alzheimer's disease Mol Psychiatry 19 2014 1227 1234
83. B.M. Brown, J.J. Peiffer, K. Taddei, J.K. Lui, S.M. Laws, V.B. Gupta for the AIBL Research Group Physical activity and amyloid-β plasma and brain levels: results from the Australian, Imaging, Biomarkers and Lifestyle Study of Ageing Mol Psychiatry 18 2013 875 881
84. Q. Zhigang, and L. Kuncheng Update of China-ADNI 2013 Available at http://www.alz.org/research/funding/partnerships/2013-meeting/21-China-ADNI.pdf Accessed June 15, 2015
85. China-ADNI project overview. 2013. Available at: http://english.baad.org.cn/China-ADNI/project/index.shtml. Accessed June 15, 2015.
86. China-ADNI Organization overview. 2013. Available at: http://english.baad.org.cn/China-ADNI/organization/index.shtml. Accessed June 15, 2015.
87. E. Liu, J. Luthman, J.M. Cedarbaum, M. Schmidt, P.E. Cole, and et al. Perspective: The Alzheimer's Disease Neuroimaging Initiative and the Role and Contributions of the Private Partner Scientific Advisory Board (PPSB) Alzheimers Dement 11 2015 840 849